The table below shows GeneDx Holdings Corp.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$32.41M
$10.18M
-$16.41M
-$55.56M
-$81.49M
-$42.21M
Capital expenditure
$6.45M
$6.13M
$443.00K
$0.00
$1.38M
$2.08M
Investing cash flow
-$17.25M
-$9.41M
$843.00K
-$462.00K
-$3.91M
-$4.99M
Dividends paid
-
-
-
-
WGS operating cash flow (10-K history)
GeneDx Holdings Corp. reported operating cash flow of $33.28M for fiscal year 2025. That is up 216.8% from -$28.50M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow grew from -$18.73M (FY 2019) to $33.28M. Figures come from the company's audited annual reports as filed with the SEC.